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GvHD is a major complication of allogeneic hematopoietic stem
cell transplantation (aHSCT), and is mediated by cytotoxic T cells
(CTLs), recruited by chemokines such as CXCL9/MIG, CXCL10/IP-10
and CXCL11/ITAC to target organs, where they effect tissue
injury.1,2
B-cell contribution to GvHD pathogenesis is widely accepted,
but only partially explained. The role of B cells in the pathogenesis
of immune responses is multifold, including Ab-mediated and
-independent mechanisms, such as Ag presentation, and cytokine
production.3
B cells from GvHD patients show altered homeostasis,
conditioned by an unbalanced immune milieu, including
abnormal B-cell activating factor (BAFF) concentrations, and
leading to the differentiation of activated CD27 B cells sponta-
neously producing Igs.4
We described an interaction between autologous CD19 B cells
and activated CD8 CTLs in normal donors.5 In vitro Ag-stimulated
CTLs form stable couplets with B cells independent of Ag
presentation, through CD27 (on B cells)–CD70 (on T cells) axis.
T-cell/B-cell coupling enhances CTL survival and proliferation, and
stimulates cytokine release by B cells, including CXCL9/MIG,
CXCL10/IP-10 and CXCL11/ITAC.
The CD27-70 interaction has a central role in B–T cross talk and
activation6–8 by promoting the development of the T-cell
effector pool9 and activating CTL-effector functions,10 while
contemporaneously inducing B-cell activation, expansion and
differentiation into plasma cells.11
Interestingly, the pattern of cytokines secreted by B cells after
coupling is consistent with their role in promoting migration of
T cells to GvHD-affected organs.1
Here, we explored the interactions of B cells with CD8 cells in
blood and tissues of GvHD patients.
We ﬁrst performed a single-center study, retrospectively
analyzing consecutive blood samples from 81 transplanted
patients and 21 healthy controls, processed in the Central Hospital
of Bolzano for immune-monitoring purposes (identiﬁcation
cohort). To comprehensively study the role of CD19–CD8 coupling
in GvHD, we included patients with45% of circulating CD19 cells,
targeting therefore late acute and chronic forms, regardless of
the ongoing therapy (details in Supplementary Tables 1S and 2S).
The frequency of coupling was calculated as the percentage of
viable CD45++/CD8++/CD19+ cells (Figure 1a). Interestingly, the
ﬂow cytometry appearance of the couplet resembled a single
CD8++/CD19+ event, whereas we already demonstrated that, by
means of cell sorting, this cell population could be separated
by ﬂuid shear stress in single CD8 and CD19 cells.5 Double-positive
cells displayed consistently high forward scatter (FSC)/side scatter
(SSC) scores (examples in Figure 1, Supplementary Figure 2S).
Couplets stained negative for CD16, CD56, CD4 and positive for
CD3 (data not shown).
We included samples collected only from patients with active
GvHD, and a relatively recent onset, setting an arbitrary 150 days
limit from onset. Non-GvHD controls included patients without
previous or suspect GvHD.
As a further control, to rule out the inﬂuence of infection on
coupling, we excluded patients and controls with known active
viral and bacterial infections at the time of sampling. However, the
frequency of couplets was not signiﬁcantly different among
patients with and without infections and no GvHD (data not
shown), suggesting that the coupling occurs independently.
The ﬁnal number of evaluable samples was 20 GvHD samples,
15 non-GvHD controls, 21 healthy controls (details and statistical
methods in Supplementary Table 1S).
Seven patients in the identiﬁcation cohort were monitored
before and after GvHD onset. B–T couplets were signiﬁcantly
higher in patients after GvHD onset and overall in the GvHD
patient cohort compared with aHSCT patients without GvHD and
healthy controls (Figures 1b and c).
The GvHD cohort included a subgroup of patients with
percentage of couplets above the median value. This subgroup
was otherwise similar in clinical characteristics (transplant type,
stem cell source, type and grade of GvHD) to the other GvHD
patients, save for the time after GvHD onset: patients analyzed
within 30 days from GvHD onset had higher rate of couplets
(Figure 1c, red dots).
Nine patients in the aHSCT cohort received therapeutic donor
lymphocyte infusions (DLIs) for disease relapse. Couplets were
signiﬁcantly higher after DLI (Figure 1d) regardless of the
subsequent GvHD development and disease response.
DLIs are composed by mixed lymphocytes, including B cells.
Hence, we tested whether coupling correlated with the quantity of
circulating B cells. This was true only for coupling after DLI, not
after GvHD, suggesting that in GvHD the development of couplets
is enhanced over their stochastic occurrence observed in the
presence of higher B-cell numbers owing to DLI (Figures 2a and b).
Our ﬁndings were validated prospectively in an independent
patient cohort (veriﬁcation cohort).
Thirty-four consecutive samples from 23 pediatric patients
transplanted in S Matteo Hospital of Pavia, were stained with
CD45, CD3, CD8 and CD19 Abs after ﬁcoll enrichment. Analyses
were performed on FSC/SSC viable CD45+CD19+CD8++ cells. All
patients had ⩾ 50 blood B cells/μL. Patients were categorized as
previously described (Supplementary Table 1S). Because of the
limited number of patients, we also analyzed the data at any time
after GvHD onset. Both analyses conﬁrmed signiﬁcantly higher
CD19–CD8 couplets in GvHD patients (Figures 2c and d). Again,
the percentage of couplets in patients developing GvHD within
30 days from sampling was higher.
Eleven patients in both cohorts had longitudinal post-GvHD
samples. The kinetics of couplets with time distinguished
signiﬁcantly the GvHD group (P= 0.01, Supplementary Figure 1S).
We conﬁrmed the coupling phenomenon in an additional small
GvHD patient cohort in Würzburg University Hospital. In this
independent analysis, thawed samples were analyzed for B–T
activation markers, which resulted speciﬁcally enhanced in the
couplet (Supplementary Figure 2S).
Within the limitation of this preliminary study, we analyzed
several clinical variables like severity of GvHD, GvHD outcome,
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ongoing therapy, but no relevant association other than time after
GvHD onset emerged in the cohorts (Supplementary Table 2S).
Finally, we analyzed the presence and tissue distribution of B–T
couplets in skin and gastrointestinal (GI) biopsies of GvHD tissues.
Thirteen GvHD samples from 12 aHSCT patients (4 GI and 9 skin
biopsies) and 8 from controls (3 GI and 5 skin biopsies),
including 6 aHSCT patients without GvHD and 2 healthy
controls, were collected in Bolzano Hospital and analyzed
by immunohistochemistry (IHC), or laser scanner microscopy
(LSM; Supplementary Table 3S).12
B cells are usually absent in normal skin and very rare in GvHD
skin, as other groups failed to ﬁnd evidence of them.13
By including also the slides with low numbers of B cells (1–10),
we visualized CD8–CD19/20 couplets in skin and GI GvHD
biopsies. Two independent analyses with different imaging
platforms (IHC and LSM) conﬁrmed higher couplets number in
GvHD patients (Figure 2e, Supplementary Table 3S).
CD19–CD8 coupling is an intriguing phenomenon that we
characterized in depth in Flu-Ag-speciﬁc CTLs expanded in vitro,
demonstrating that it stimulates a pro-inﬂammatory interaction
through CD27–CD70 contact and through secretion of soluble
molecules.
This preliminary study aimed to verify the relevance of this
in vitro observation in GvHD. The study captured data collected
for clinical immune-monitoring purposes and only a limited
immunophenotyping of the couplets was feasible. Conceivably,
based on our preliminary data, the couplet is formed by
donor-derived CD27+ B cells and CD70+ CTLs, but this has to
be conﬁrmed with deep phenotyping and lineage-speciﬁc
chimerism analyses in a future larger prospective study. This
future study could also better address immunologic variables
potentially connected with coupling, as response to GvHD therapy
or relapse.
The frequency of couplets observed in vivo rarely exceeds 0.5%
of circulating CD45 lymphocytes. However, it is reproducibly and
speciﬁcally detectable in GvHD patients early after diagnosis and
regardless of therapy. Three patient cohorts independently
analyzed with different methods (fresh blood, ﬁcoll enrichment,
thawed cells) demonstrated signiﬁcantly the presence of couplets.
This reproducibility could suggest the use of coupling as a GvHD
biomarker.
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Figure 1. (a) Flow-cytometer analysis logical gating. Only couplets in the CD8 bright ﬁeld are scored in the analysis. Back-gate row shows
physical parameters of the CD8–CD19 cells in the regions. (b) Patients monitored before and after GvHD onset (median 33 days after GvHD
onset: 15–116) measured with Wilcoxon matched-paired rank test. Median (min–max) values for the groups are: pre-GvHD 0 (0–0.21);
post-GvHD 0.13 (0–0.38). (c) Couplets scoring in aHSCT patients and healthy controls, measured with Kruskal–Wallis unpaired test. Red dots
are patients screened within 30 days after GvHD onset, black dots within 150 days. Median (min–max) values for the groups are: GvHD 0.115
(0–0.8); no GvHD 0.038 (0–0.22); healthy controls (HC) 0.072 (0–0.18). (d) Patients analyzed pre- and post DLI (median 29 days after DLI: 11–126)
measured with Wilcoxon matched-paired rank test. Median (min–max) values for the groups are: pre-DLI 0 (0–0.13); post-DLI 0.13 (0.025–1).
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Coupling was also present after DLI and correlated with a
number of circulating B cells, suggesting that this is a relevant
substrate for these interactions that are likely more stable, and
frequent when T or B cells are in an active functional status as in
the case of GvHD.
One limitation of the study is the lack of imaging of the couplet
in ﬂow cytometry analyses.
We rely on bona ﬁde couplets after verifying high FSC–SSC
parameters and after demonstrating in our previous work the
sorting-based physical separation of the couplet.5
We cannot rule out membrane sharing between the two cell
types after contact, and therefore the risk of overestimation by
counting as a couplet a single cell that acquired the marker of the
other lineage. In this case, the data would rather reﬂect a
signiﬁcant difference in coupling dynamics in GvHD, and still be
valuable as a biomarker.
Tissue biopsies showed evidence of coupling, also involving
limited amounts of cells.
As coupling is a transient phenomenon, a single time point
sampling and tissue biopsy may not adequately describe a dynamic
interaction. When we described in vitro CD19–CD8 coupling, we
performed overnight time-lapse analyses showing that T cells
engaged prolonged and multiple contacts with rather static B cells
(http://www.jimmunol.org/content/180/3/1362/suppl/DC1).
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Figure 2. Linear regression analysis correlating number of peripheral blood B cells, and % of couplets in patients post DLI (a), and post-GvHD
onset (b) identiﬁcation patient set. Red dots are patients who developed GvHD post DLI. Same analyses correlating CD8 baseline cells did not
achieve signiﬁcance (P= 0.617 and r2= 0.038 post DLI, and P= 0.579, r2= 0.064 post GvHD). (c and d) Couplet scoring in aHSCT pediatric
patients veriﬁcation population, measured with Mann–Whitney unpaired tests. Black dots include all GvHD patients (c) and patients analyzed
within 150 days after GvHD (d). Red dots are patients screened for couplets within 30 days after GvHD onset. Median (min–max) values for the
groups are: 0.2 (0–0.9) and 0.2 (0–0.6) for GvHD patients in c and d, respectively; 0.1 (0–0.2) for both no-GvHD controls. (e) IHC staining on
parafﬁne-embedded GvHD tissues (i, ii), and LSM on deparafﬁnized samples (iii, iv) showing examples of CD8 and CD19 coupling in GvHD
tissues. See Supplementary Table 2S for more data.
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A GvHD animal model could be more suitable for such in vivo
investigation, also facilitating couplet analysis in lymphoid tissues,
where similar interactions may take place.
We speculate that a cross talk between CD19 and CD8
lymphocytes triggers immunologic responses relevant to GvHD.
This deserves further investigation and validation in a prospective
study, speciﬁcally designed to capture the immunological trigger
behind the coupling and the fate of the cells after this interaction.
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